| Literature DB >> 31890258 |
Micol Artom1, Wladyslawa Czuber-Dochan1, Jackie Sturt1, Hannah Proudfoot2, Danniella Roberts1, Christine Norton1.
Abstract
BACKGROUND: Fatigue is the third most prevalent symptom for patients with inflammatory bowel disease (IBD), yet optimal strategies for its management are unclear. Treatment protocols for fatigue in other conditions have been based on cognitive-behavioural models. Targeting cognitions, emotions and behaviour related to fatigue through cognitive-behavioural therapy (CBT) may be a viable option to improve fatigue and quality of life (QoL) in IBD.Entities:
Year: 2019 PMID: 31890258 PMCID: PMC6905023 DOI: 10.1186/s40814-019-0538-y
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
Feasibility and acceptability outcomes
| Outcome | Objectives | Methods | Progression criteria |
|---|---|---|---|
| Recruitment | Assess the feasibility of recruiting eligible participants; assess the willingness of participants to be randomised | Recruitment log; screening log; record of reasons for participation refusal | ≥ 50% of eligible participants will consent for participation in the study |
| Completeness of outcome data measures | Assess the completeness of the outcome data questionnaire booklets | Outcome data questionnaire booklets | ≤10% missing data in each completed questionnaire booklet |
| Compliance | Evaluate the compliance rates of participants to the intervention | Post-intervention follow-up questionnaire with participants; semi-structured interviews with therapists | 90% of participants will read all the sessions of the manual; ≥ 15 min per week will be spent completing tasks in relation to the intervention |
| Retention | Assess withdrawal rates during the intervention support sessions; assess the completion rates of the outcome measures at follow-up | Recruitment log therapist session log of participants’ compliance; semi-structured interviews with participants | ≥ 80% of those consented will start the intervention; ≥ 70% of participants who start will complete all 8 therapist support sessions; ≤ 20% of participants will withdraw from the intervention support sessions; ≥ 70% of participants will complete baseline and 3-month follow-ups |
| Delivery | Evaluate therapists’ views on the intervention delivery | Semi-structured interviews with therapists | There will be positive opinions from the therapists regarding the feasibility of delivering the intervention |
| Implementation | Evaluate HCPs views on the intervention implementation | Semi-structured interviews with HCPs working with people with IBD | There will be support from HCPs regarding the feasibility of implementation of the intervention |
| Acceptability of the intervention | Evaluate participants’ experience of the intervention | Semi-structured interviews with a sub-set participants in Group 1; post-intervention follow-up questionnaire | There will be positive opinions from participants regarding an acceptably positive experience of taking part in the intervention |
IBD inflammatory bowel disease, HCPs healthcare professionals
RCT patient participants’ baseline characteristics
| Variable, | Intervention Group 1 (15) | Control Group 2 (16) |
|---|---|---|
| Female gender | 10 (67) | 10 (62) |
| Age, mean (range), years | 37.00 (31) | 39.13 (33) |
| Education | ||
| Up to 16 | 1 (6.6) | 2 (12.5) |
| Up to 18 | 0 | 1 (6.2) |
| Higher education | 14 (93.3) | 13 (81.2) |
| Marital status | ||
| Married/living with partner | 9 (60) | 11 (68.7) |
| Widowed/divorced | 2 (13.3) | 0 |
| Single/single parent/Other | 4 (26.7) | 5 (31.2) |
| Employment status | ||
| Full time/part time | 14 (93.3) | 13 (81.2) |
| Retired | 0 | 0 |
| Not working/housekeeping | 1 (6.6) | 3 (18.8) |
| Living status | ||
| Alone | 2 (13.3) | 3 (18.8) |
| With partner/spouse/child/ other relatives/friends | 13 (86.7) | 13 (81.2) |
| Smoking status | ||
| Yes | 0 | 1 (6.2) |
| Ex-smoker | 5 (33.3) | 9 (56.2) |
| No | 10 (66.7) | 6 (37.5) |
| Exercise status (weekly) | ||
| > 30 min aerobic exercise | 12 (80) | 10 (62.5) |
| < 30 min aerobic exercise | 3 (20) | 6 (37.5) |
| Disease classification | ||
| UC | 3 (20) | 4 (25) |
| CD | 11 (73.4) | 10 (62.5) |
| IBDU | 1 (6.6) | 2 (12.5) |
| CD Montreal classification ( | ||
| L1 ileal | 6 (60) | 3 (30) |
| L2 colonic | 0 | 4 (40) |
| L3 ileocolonic | 4 (40) | 3 (30) |
| Months since diagnosis, median (range) | 171.13 (879) | 217.00 (972) |
| Current medication (yes) | 10 (67) | 14 (87) |
| Thiopurines | 6 | 6 |
| Methotrexate | 0 | 1 |
| Anti-TNF | 7 | 4 |
| Vedolizumab | 0 | 2 |
| Steroids | 0 | 1 |
| Previous IBD surgery (yes) | 1 (6.67) | 4 (25) |
| Current stoma (yes) | 0 | 1 (6.2) |
anti-TNF Anti-Tumour Necrosis Factor, CD Crohn’s Disease, IBD Inflammatory Bowel Disease, IBDU inflammatory bowel disease unclassified, UC ulcerative colitis
Fig. 1Consort diagram of patient flow
Means and standard deviations of outcome measures of all participants at baseline, 3, 6 and 12 months’ follow-up measures
| Outcome | Group | Baseline | 3-month follow-up | 6-month follow-up | 12-month follow-up | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||||||
| HBI | Group 1 | 3.30 | 3.2 | 10 | 5.50 | 6.05 | 8 | 11.20 | 5.45 | 5 | 8.00 | 2.45 | 5 |
| Group 2 | 4.33 | 2.74 | 9 | 5.50 | 4.46 | 6 | 7.80 | 3.70 | 5 | 5.00 | 0.00 | 3 | |
| SCCAI | Group 1 | 5.22 | 3.22 | 3 | 4.00 | 2.83 | 2 | 7 | 0 | 1 | 11.00 | 4.24 | 2 |
| Group 2 | 4.50 | 2.52 | 4 | 4.50 | 1.22 | 6 | 8.67 | 1.16 | 3 | 7.50 | 0.71 | 2 | |
| IBD-F1 | Group 1 | 11.93 | 3.24 | 14 | 8.00 | 4.61 | 9 | 7.83 | 3.66 | 6 | 8.43 | 2.51 | 7 |
| Group 2 | 9.93 | 4.13 | 15 | 9.45 | 4.97 | 11 | 8.13 | 4.16 | 8 | 8.00 | 2.65 | 5 | |
| IBD-F2 | Group 1 | 55.83 | 26.74 | 12 | 23.40 | 15.09 | 10 | 31.75 | 25.86 | 6 | 29.85 | 18.89 | 7 |
| Group 2 | 49.00 | 28.66 | 15 | 44.20 | 30.96 | 10 | 23.49 | 25.33 | 8 | 21.05 | 12.66 | 5 | |
| IBDQ | Group 1 | 89.67 | 13.67 | 15 | 97.50 | 11.20 | 10 | 91.83 | 18.70 | 6 | 97.57 | 8.89 | 7 |
| Group 2 | 93.79 | 8.87 | 14 | 95.27 | 10.10 | 11 | 100.88 | 10.86 | 8 | 100.00 | 4.30 | 5 | |
| BIPQ | Group 1 | 41.13 | 6.20 | 15 | 32.40 | 6.83 | 10 | ||||||
| Group 2 | 42.40 | 7.14 | 15 | 43.20 | 6.14 | 10 | |||||||
| ESS | Group 1 | 13.87 | 4.85 | 15 | 7.00 | 4.42 | 10 | ||||||
| Group 2 | 10.19 | 4.69 | 16 | 9.82 | 3.90 | 11 | |||||||
| GAD7 | Group 1 | 9.80 | 5.54 | 15 | 4.50 | 3.53 | 10 | ||||||
| Group 2 | 8.00 | 5.27 | 16 | 5.00 | 3.52 | 11 | |||||||
| PHQ9 | Group 1 | 12.00 | 6.01 | 15 | 6.00 | 4.42 | 10 | ||||||
| Group 2 | 9.75 | 6.00 | 16 | 8.73 | 4.71 | 11 | |||||||
BIPQ Brief Illness Perceptions Questionnaire, ESS Epworth Sleepiness Scale, GAD generalised anxiety disorder, HBI Harvey Bradshaw Index, IBD-F Inflammatory Bowel Disease-Fatigue, IBDQ Inflammatory Bowel Disease Questionnaire, PHQ Patient Health Questionnaire, SCCAI Simple Clinical Colitis Activity Index, SD standard deviation
Means, standard deviations, change scores and effect sizes of participants who completed baseline and 3 months’ follow-up primary and secondary outcome measures
| Outcome | Group | Baseline | 3 months’ follow-up | Change scores | Between group effect sizes (CI) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | MD (CI) | ||||
| IBDF-1 | Group 1 | 11.12 | 3.56 | 7.00 | 3.74 | 8 | − 4.12 | 4.91 | − 2.94 (− 7.21, 1.32) | 0.84 (− 0.5, 1.82) |
| Group 2 | 10.63 | 4.25 | 9.45 | 4.87 | 11 | − 1.18 | 2.28 | |||
| IBDF-2 | Group 1 | 53.25 | 31.67 | 23.00 | 16.38 | 8 | − 30.25 | 23.90 | − 26.14 (− 29.30, − 2.98) | 1.20 (0.13, 2.27) |
| Group 2 | 51.44 | 33.24 | 47.33 | 31.11 | 9 | − 4.11 | 20.08 | |||
| IBDQ | Group 1 | 90.80 | 15.08 | 97.50 | 11.20 | 10 | 6.70 | 11.09 | 2.70 (− 6.45, 11.85) | − 0.25 (− 1.21, 0.72) |
| Group 2 | 91.70 | 9.79 | 95.70 | 10.54 | 10 | 4.40 | 8.01 | |||
CI confidence interval, IBD-F Inflammatory Bowel Disease-Fatigue, IBDQ Inflammatory Bowel Disease Questionnaire MD mean difference, SD standard deviation